Bio-Works Technologies’ annual general meeting was held on 15 May 2025.

In her address to the Annual General Meeting, CEO Lone Carlbom provided a summary of the past year and made the following remarks regarding the company’s current trajectory:

“As we look ahead, we see a strong start to 2025 – marked by a record-high order intake, enhanced delivery capacity, and a team that is more cohesive, driven, and energized than ever before.

We are well positioned to take the next step.

With a promising pipeline, dedicated employees, and a clear objective – to become a profitable, sustainable, and leading company within our niche in the biopharma industry – we enter the new year with high ambitions and strong confidence.”

The following resolutions were passed at the annual general meeting, among other resolutions.

The meeting adopted the income statement and balance sheet and the consolidated income statement and consolidated balance sheet for the financial year 2024.

The meeting resolved that no dividend shall be paid for the financial year 2024.

The meeting granted the board members and CEOs discharge from liability for the financial year 2024.

The meeting resolved that the number of board members shall be four and re-elected Peter von Ehrenheim, Jonas Ahlen, Thomas Gür, and Peter Nählstedt. Kirsti Gjellan had declined re-election. Peter von Ehrenheim was re-elected as chairman of the board. The meeting resolved that directors’ fees of SEK 260,000 shall be paid to the chairman of the board and SEK 130,000 to each of the other directors not employed by the company. In addition to director fees, no fees shall be paid for work on the board’s committees.

Öhrlings PricewaterhouseCoopers AB was re-elected as auditor. Niclas Bergenmo will be the auditor in charge. The auditor's fee shall be paid in accordance with approved invoice.

The meeting resolved on new instructions for the nomination committee, to apply until the general meeting decides otherwise.

The meeting resolved, in accordance with the board’s proposal, to authorize the board for the period until the next annual general meeting, on one or more occasions, with or without preferential rights for shareholders, to decide on issue of new shares. The authorization includes shares corresponding to a maximum of ten (10) percent of the total number of issued shares in the Company at the time when the board first utilizes the authorization. The purpose of the authorization is to increase the company’s financial flexibility and the board’s margin for maneuver. If the board decides to issue shares with deviation from the shareholders' preferential rights, the reason shall be to broaden the owner circle, raise working capital, acquire companies or businesses or to acquire capital for such acquisitions.

The annual general meeting minutes, including complete resolutions, will shortly be published on the company’s website.

Contacts:
For more information, please visit the Bio-Works homepage at, www.bio-works.com or contact: Lone Carlbom, CEO, e-mail: lone.carlbom@bio-works.com, phone: +46(0)8-502 705 84.

About Bio-Works
Bio-Works enables Biotech companies to achieve their goals for purification of biomolecules. We support our customers, from laboratory research to commercial production, and together we implement efficient and robust solutions for bioprocessing. Our ambition is to be a trusted and dynamic partner in an industry characterized by growth and development.

Bio-Works’ headquarters, with R&D and manufacturing, is located in Uppsala Business Park in Uppsala, Sweden. We supply products globally, through a combination of direct sales and via distributors in Europe, North America and Asia. The company is certified according to the ISO 9001:2015 quality management system. Bio-Works is listed on Spotlight Stock Market ("BIOWKS"). For more information, visit www.bio-works.com.